First high-sensitivity troponin I assay available in the United States enables clinicians to provide efficiency improvements in cardiac patient management
Access hsTnI, a true high-sensitivity troponin I assay, demonstrates <10% CV at the upper reference limits (URL) for men and women and detects troponin in >50% of the healthy population. In an independent study, Access hsTnI detected >99% of troponin values for healthy men and women.1 As the only high-sensitivity troponin I assay available in the U.S., Access hsTnI enables clinical laboratories to confidently report accurate results for clinical decision making in the acute-care setting. Laboratories have increased testing flexibility with this assay as it is the only high-sensitivity assay to use either plasma or serum samples.
Heart disease is the number one cause of death in the U.S. Every 40 seconds, someone experiences an MI, and, every year, chest pain and related symptoms send 8 million patients to the emergency department (ED).2 Only 5.5% of those entering the ED, however, are diagnosed with a serious condition, including MI.3 Beckman Coulter Diagnostics is committed to helping clinical partners focus on diagnosing MI and other significant cardiac events faster and with greater accuracy. The Access hsTnI assay helps clinicians to accurately identify ≥94% of true acute MI patients in as little as one hour after patient presentation.
“Beckman Coulter's high-sensitivity cardiac troponin I assay can measure very low cardiac troponin concentrations with excellent precision. This test may help physicians with both the early diagnosis of myocardial infarction and future risk stratification in and outside the acute coronary syndrome setting,” said Peter Kavsak, Ph.D., associate professor, Department of Pathology and Molecular Medicine at McMaster University.
The Access hsTnI assay features high-sensitivity performance for excellent low-end sensitivity, providing a reliable measurement of very low levels of cardiac troponin I (cTnI), while also detecting small differences in cTnI levels over time. In comparison to standard troponin assays, high-sensitivity assays demonstrate significantly improved precision at and below the 99th percentile URL, allowing better discrimination of small differences in troponin values between serial measurements.
“The most common cause of death in women is heart disease. Women sometimes do not exhibit the same symptoms as men when experiencing a heart attack. Because women tend to have lower troponin levels than men, their treatment may be delayed,” said Michael Samoszuk, M.D., vice president and chief medical officer, Beckman Coulter Diagnostics. “Access hsTnI enables more accurate identification of women with myocardial infarction by providing separate sex-specific upper reference limits.”
More precise determination of the 99th percentile URL has also led to an ability to report distinct reference ranges for men and women. Multiple studies confirm that high-sensitivity assays detect cTnl release earlier, increasing sensitivity for MI diagnosis at presentation. This may help physicians to diagnose MI earlier in the course of care.
Access hsTnI utilizes a new robust design to minimize the effects of pre-analytical variability and known interferences. This new design helps deliver high-quality results needed to distinguish between MI and other cardiac conditions. It will help with rapid MI diagnosis and enable physicians to confidently exclude MI in as little as one hour after patient presentation to the ED, providing efficiency improvements in cardiac patient management.
Beckman Coulter, a leader in immunoassay testing, continues to lead assay innovation with the launch of Access hsTnI. In addition, Beckman Coulter has expanded and refreshed its assay menu to include Access Sensitive Estradiol, Anti-Müllerian hormone, thyroid-stimulating hormone, vitamin D and beta-human chorionic gonadotropin. These products have been designed to meet customer needs and new industry and regulatory guidelines.